Evidence map›Paper›PMID 41354342›Full record

ReviewThe Journal of biological chemistry2026

Coordinated regulation of Capping Protein by CARMIL and V-1/myotrophin.

John A Hammer, John A Cooper

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

John A HammerCell and Developmental Biology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: HammerJ@nhlbi.nih.gov.
John A CooperDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, Missouri, USA. Electronic address: jcooper11@gmail.com.

Funding

Allosteric Regulation of Actin Capping Protein: Mechanism and SignificanceR35GM144082 · NIGMS · WASHINGTON UNIVERSITY · PI JOHN A COOPER · 2022 to 2026
$2.8M
NIGMS NIH HHS R35 GM144082
6 · The paper itself

Abstract

Capping Protein (CP) plays a central role in controlling actin filament dynamics in almost all eukaryotic cell types by virtue of its ability to block monomer addition and loss at the barbed end of the actin filament. Like other proteins that control actin assembly, CP is subject to regulation. Here we focus on two direct regulators of CP-CARMIL and V-1/Myotrophin. Specifically, we review recent biochemical, structural, imaging, and cell biological data that argue these two proteins cooperate to create a regulatory cycle for CP that controls its availability, activity, and site of action in the cell. Finally, we discuss unresolved aspects of this regulatory cycle and highlight how it may provide the cell with new avenues for adjusting its "actin phenotype".

Indexed as

Actin Capping ProteinsActin CytoskeletonAnimalsHumansIntercellular Signaling Peptides and ProteinsActin Capping ProteinsIntercellular Signaling Peptides and Proteinsmyotrophinactinallosteric regulationArp2/3 complexCapping ProteinCARMILcell migrationcell motilitymyotrophinV-1

Identifiers

PMID41354342
PMCPMC12803934

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.